… development of postoperative venous thromboembolism. Factor XI inhibition with a single
… was effective for the prevention of venous thromboembolism and was associated with a low …

… VTE treatment, bleeding remains the major side effect, particularly in cancer patients. Factor
XII and factor XI have … and apixaban in the Factor XIa Inhibition for the Prevention of Venous …

… to determine the incidence of deep-vein thrombosis after surgery. In such patients, …
factor XI levels or postoperative factor XI inhibition with intravenous abelacimab, a factor XI–…

… , by preventing the adoption of an effective antithrombotic strategy). Inhibition of factor XI (FXI) …
In most cases of arterial and venous thrombosis, FXI is activated by thrombin resulting from …

… factor XI antisense oligonucleotides were successful in lowering factor XI levels and preventing
… Whether this result is confirmed with oral or long-acting parenteral factor XI inhibitors in …

… would provide opportunities for treatment of a wider range of … to which factor XI inhibitors
attenuate thrombosis without … underlying mechanism of venous thromboembolism (VTE) and …

The most important decision in the long-term treatment of venous thromboembolism (VTE)
is how long to anticoagulate. VTE provoked by a reversible risk factor, or a first unprovoked …

… This article (1) reviews the rationale for the development of factor XI inhibitors, (2) identifies
… Ir-CPI attenuated arterial and venous thrombosis in murine models,[20] prolonged the time …

… June 2020 for randomized clinical trials, meta-analyses, systematic reviews, and observational
studies. Risk factors for venous thromboembolism (VTE), such as older age, malignancy (…

… Concomitant venous thromboembolism (VTE), a potential cause of unexplained deaths, has
been frequently reported in COVID-19 cases, but its management is still challenging due to …